The board of directors of Lee's Pharmaceutical Holdings Limited announced that after considering the recommendation of the nomination committee of the Company, the Board has appointed Mr. Huang Zuie Chin as a non-executive Director with effect from 2 July 2024. Mr. Huang, aged 59, has over 35 years' experience in the life science and investment industry together with 20 years' experience in the pharmaceutical and biotech industry holding senior roles in business development, sales, marketing and research and development. In 2011, he joined Kleiner Perkins Caufield & Byers China as a managing partner and focuses on the firm's life science practice.

He is also the founding managing partner of Panacea Healthcare Venture Capital, including Panacea Venture Healthcare Fund I, L.P., Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P., which are venture capitals focusing on investments in innovative and transformative early and growth stage healthcare and life sciences companies worldwide. Mr. Huang received a Master of Business Administration (MBA) from the Stanford Graduate School of Business and a Bachelor of Science degree in chemical engineering from the University of California, Berkeley. He is a non-executive director of Kindstar Globalgene Technology Inc., whose shares are listed on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") (Stock Code: 9960) since 2012, and a director of Connect Biopharma Holdings Limited, a company whose shares are listed on Nasdaq Global Market since 2024.

Between 2020 and 2023, he was an executive director of Auto Italia Holdings Limited, whose shares are listed on the Stock Exchange (Stock Code: 720). Furthermore, Mr. Huang was the chairman of the board of directors of Alaunos Therapeutics Inc., whose shares are listed on NASDAQ Global Select Market, between 2021 and 2023. He was also a director of CASI PHARMACEUTICALS, INC., whose shares are listed on NASDAQ, between 2013 and 2023 and the chairman of the board of Windtree Therapeutics Inc., a company whose shares are listed on NASDAQ between 2019 and 2023.